Skip to content

Implementation of an RT-PCR Assay for the Diagnosis of Rickettsia Spp. Infection

Implementation of an RT-PCR Assay for the Diagnosis of Rickettsia Spp. Infection

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07307651
Enrollment
800
Registered
2025-12-29
Start date
2026-01-07
Completion date
2029-06-07
Last updated
2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Rickettsia Infections

Brief summary

Rickettsia2024 is a multicenter, tissue observational, retrospective and prospective cohort study. Enrollment will take place within the outpatient clinics of the Infectious Diseases and Dermatology Unit of the IRCCS AOUBO and, following an infectious disease consultation in the Bologna Metropolitan area, at the Hospitals and CAUs of the Bologna Local Health Authority. Within these UUOOs, biopsy samples from normal clinical practice are performed on patients with strong clinical suspicion of Rickettsia infection: therefore, it will not be necessary to perform any additional samples for the conduct of this study. Samples from the normal diagnostic process are sent to the Microbiology UOC, where they are subjected to various analyses. RT-PCR analyses (commercial or in-house kit) and assay of species-specific IgG antibodies will be performed according to clinical practice. Additional tests will be performed with a commercial kit for retrospective samples and with a home-made method for prospective samples.

Detailed description

It is estimated that a total of approximately 800 patients can be recruited, 400 for the retrospective part and the same number for the prospective part (estimated using data collected from requests received to date). For the retrospective cohort: from January 2023 until approval by the ethics committee; For the prospective cohort: from ethics committee approval until December 2027.

Interventions

None listed

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* pazienti che presentano escara * pazienti con richiesta del dosaggio degli anticorpi anti-Rickettsia conorii

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
To evaluate the early diagnostic capability of molecular testing (RT-PCR) for the diagnosis of Rickettsia infection at the time of first blood sampling in suspected cases.from January 7, 2026 to June 7, 2028

Secondary

MeasureTime frame
Comparison of the sensitivity and specificity of diagnosis of in-house RT-PCR and commercial kit (Rickettsia spp REAL TIME PCR, Immunospark)from January 7, 2026 to June 7, 2028
Identification of Rickettsia species by gene sequencing of the 16S rRNA portion of samples tested positive (threshold cycle < 30) by in-house RT-PCR/commercial kitfrom January 7, 2026 to June 7, 2028
Estimation of the incidence of Rickettsia conorii infections in the Bologna metropolitan area through serological screeningfrom January 7, 2026 to June 7, 2028

Countries

Italy

Contacts

Primary ContactSilvia Galli
silvia.galli@aosp.bo.it+39 0512144450
Backup ContactGiulio Virgili, MD
giulio.virgili@aosp.bo.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026